Wockhardt Limited announced today that its novel antibiotic WCK 6777 (Ertapenem/Zidebactam) has been granted Fast Track designation by the USFDA for treating complicated urinary tract and intra-abdominal infections. The drug has also successfully completed a Phase I study conducted by the National Institutes of Health (NIH) in the United States.
The shares of Wockhardt Limited were trading at ₹941.35 down by ₹24.15 or 2.50 per cent on the NSE today at 12.11 pm
WCK 6777, a once-daily β-lactam enhancer, is designed for outpatient parenteral antimicrobial therapy. It targets multi-drug resistant Gram-negative pathogens in both community and hospital settings. The Phase I study, involving 52 participants, demonstrated a promising safety profile with no serious adverse events reported.
The antibiotic is positioned to address the significant unmet need in managing infections outside hospitals. It is active against carbapenem-resistant pathogens, including those producing metallo β-lactamases.
Wockhardt’s drug discovery efforts have resulted in a portfolio of six products at various stages of development, each granted Qualified Infectious Disease Product status by the USFDA. The company’s flagship antibiotic, Zaynich (Cepefime/Zidebactam), is currently undergoing a global Phase 3 study for extreme-drug resistant Gram-negative infections.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.